Document:

EX-10.28

 Exhibit 10.28 
 EXECUTIVE EMPLOYMENT AGREEMENT 
 for 

Curtis Ruegg, Ph. D. 
 This Executive Employment Agreement (the “Agreement”), made between Revance Therapeutics, Inc. (the “Company”) and Curtis Ruegg, Ph.D. (“Executive”)
(collectively, the “Parties”), is effective as of December 20, 2013. 

WHEREAS, Executive has been performing services for the Company pursuant to the terms of an offer
letter from the Company dated September 26, 2006 (the “Offer Letter”); and 

WHEREAS, the Company desires for Executive to continue providing services to the Company, and
Executive is willing to continue such employment by the Company, on the amended and restated terms and conditions set forth in this Agreement, which terms shall replace and supersede the terms of the Offer Letter in entirety; 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained
herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: 
 1. Employment by the Company. 
 1.1 Position. Executive shall
continue to serve as the Company’s Executive Vice President, Research and Development. During the term of Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all of
Executive’s business time and attention to the business of the Company, except for approved vacation periods and reasonable periods of illness or other incapacities permitted by the Company’s general employment policies. 

1.2 Duties and Location. Executive shall continue to perform such duties as are required by the Company’s Chief Executive
Officer, to whom Executive will report. Executive’s primary office location is currently the Company’s office located in Newark, California. The Company reserves the right to reasonably require Executive to perform Executive’s duties
at places other than Executive’s primary office location from time to time, and to require reasonable business travel. The Company may modify Executive’s job title and duties as it deems necessary and appropriate in light of the
Company’s needs and interests from time to time. 
 1.3 Policies and Procedures. The employment relationship between
the Parties shall be governed by the general employment policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this
Agreement shall control. 

  
 1. 

 2. Compensation. 

2.1 Salary. For services to be rendered hereunder, Executive shall continue to receive a base salary at the rate of three hundred
six thousand and twenty-three dollars ($306,023) per year, or in the event of a portion of a year, a pro rata amount of such annual salary (the “Base Salary”), subject to standard payroll deductions and withholdings and payable in
accordance with the Company’s regular payroll schedule. Executive’s base salary shall be reviewed by the Board of Directors for possible adjustment annually. 
 2.2 Bonus. In 2014, Executive will be eligible for an annual discretionary bonus of up to 35% of Executive’s Base Salary. The annual target bonus percentage, whether Executive receives an
annual bonus for any given year, and the amount of any such annual bonus, will be determined by the Board in its sole discretion based upon the Company’s and Executive’s achievement of objectives and milestones to be determined on an
annual basis by the Board in consultation with Executive. Bonuses are generally paid by March 15 following the applicable bonus year, and Executive must be an active employee on the date any Annual Bonus is paid in order to earn any such Annual
Bonus. Executive will not be eligible for, and will not earn, any Annual Bonus (including a prorated bonus) if Executive’s employment terminates for any reason before the date Annual Bonuses are paid. 

2.3 Standard Company Benefits. Executive shall continue to be entitled to participate in all employee benefit programs for which
Executive is eligible under the terms and conditions of the benefit plans that may be in effect from time to time and provided by the Company to its employees. The Company reserves the right to cancel or change the benefit plans or programs it
offers to its employees at any time.  
 2.4 Expenses. The Company will reimburse Executive for reasonable travel,
entertainment or other expenses incurred by Executive in furtherance or in connection with the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy and requirements of the Internal
Revenue Service as in effect from time to time.  
 2.5 Equity. Executive has been granted options to purchase
shares of the Company’s Common Stock (the “Options”), the terms of which shall continue to be governed in all respects by the governing plan documents, grant notices and stock option agreements. Executive shall be eligible to
receive further stock grants and/or stock option awards in the sole discretion of the Board. 
 3. Termination of
Employment; Severance. Executive’s employment relationship is at-will. Either Executive or the Company may terminate the employment relationship at any time, with or without cause or advance notice. Executive will be eligible for severance
under the Company’s Executive Severance Benefit Plan, adopted by the Board on December 17, 2013 and effective upon the date of the Company’s initial public offering, as it may be amended from time to time. 

  
 2. 

 4. Proprietary Information Obligations. Executive shall remain bound by the terms of
the Employee Proprietary Information and Inventions Agreement that Executive previously executed. 
 5. Outside Activities
During Employment. 
 5.1 Non-Company Business. Except with the prior written consent of the Board, Executive will not
during the term of Executive’s employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor. Executive may engage in civic and
not-for-profit activities so long as such activities do not materially interfere with the performance of Executive’s duties hereunder. 
 5.2 No Adverse Interests. Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known to be adverse or antagonistic to the Company,
its business or prospects, financial or otherwise. 
 6. Dispute Resolution. To ensure timely and economical resolution of
any disputes that may arise in connection with Executive’s employment with the Company, as a condition of Executive’s employment, Executive and the Company hereby agree that any and all claims, disputes or controversies of any nature
whatsoever arising out of, or relating to, this letter, or its interpretation, enforcement, breach, performance or execution, Executive’s employment with the Company, or the termination of such employment, shall be resolved, to the fullest
extent permitted by law, by final, binding and confidential arbitration conducted before a single arbitrator by JAMS, Inc. (“JAMS”) or its successor, under the then applicable JAMS arbitration rules (which can be found at
http://www.jamsadr.com/rules-clauses/). The arbitration shall take place in the county (or comparable governmental unit) in which Executive was last employed by the Company, as determined by the arbitrator; provided, however, that if the arbitrator
determines there will be an undue hardship to Executive to have the arbitration in such location, the arbitrator will choose an alternative appropriate location. Executive and the Company each acknowledge that by agreeing to this arbitration
procedure, both Executive and the Company waive the right to resolve any such dispute, claim or demand through a trial by jury or judge or by administrative proceeding. Executive will have the right to be represented by legal counsel at
Executive’s expense at any arbitration proceeding. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a
court proceeding; and (ii) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and
conclusions on which the award is based. The arbitrator, and not a court, shall also be authorized to determine whether the provisions of this paragraph apply to a dispute, controversy, or claim sought to be resolved in accordance with these
arbitration procedures. The Company shall pay all costs and fees in excess of the amount of court fees that Executive would be required to incur if the dispute were filed or decided in a court of law. Nothing in this Agreement is intended to prevent
either Executive or the Company from obtaining injunctive relief in court to 

  
 3. 

 
prevent irreparable harm pending the conclusion of any arbitration. 

7. General Provisions. 
 7.1 Notices. Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery (including personal delivery by fax) or the next day after sending by
overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll. 
 7.2 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is
held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will
be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties. 

7.3 Waiver. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not
thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 

7.4 Complete Agreement. This Agreement constitutes the entire agreement between Executive and the Company with regard to this
subject matter and is the complete, final, and exclusive embodiment of the Parties’ agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than
those expressly contained herein, and it supersedes any other such promises, warranties or representations, including (without limitation) the Offer Letter. It is entered into without reliance on any promise or representation other than those
expressly contained herein, and it cannot be modified or amended except in a writing signed by a duly authorized officer of the Company. 
 7.5 Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one
and the same Agreement. 
 7.6 Headings. The headings of the paragraphs hereof are inserted for convenience only and shall
not be deemed to constitute a part hereof nor to affect the meaning thereof. 
 7.7 Successors and Assigns. This Agreement
is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of his duties hereunder and he
may not assign any of his rights hereunder without the written consent of the Company, which shall not be withheld unreasonably. 

  
 4. 

 7.8 Tax Withholding and Indemnification. All payments and awards contemplated or made
pursuant to this Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any
assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and
economic consequences of all payments and awards made pursuant to the Agreement. 
 7.9 Choice of Law. All questions
concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California. 
 IN WITNESS WHEREOF, the Parties have executed this Agreement on the day and year first written above. 

 

			
	REVANCE THERAPEUTICS, INC.
		
	By:	 	 /s/ L. Daniel Browne

		 	L. Daniel Browne
		 	Chief Executive Officer

 
	
	
	EXECUTIVE
	
	 /s/ Curtis Ruegg

	Curtis Ruegg, Ph.D.

  
 5.EX-10.29

 Exhibit 10.29 
 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED. 

REVANCE THERAPEUTICS, INC. 
 WARRANT TO PURCHASE COMMON STOCK 
  

	 No. CW- 
	 December 6, 2012 

 THIS CERTIFIES THAT, for value received,
[                    ], with its principal office at
[                    ], or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from
Revance Therapeutics, Inc., a Delaware corporation (the “Company”), with its principal office at 7555 Gateway Boulevard, Newark, California 94560, the Exercise Shares (defined below). This Warrant is being issued in connection with certain
convertible promissory notes (“Notes”) issued pursuant to the terms of that certain Note and Warrant Purchase Agreement (the “Agreement”) dated as of January 24, 2011 and as amended from time to time, to the persons and
entities listed on the Schedule of Purchasers thereof. 
 1. DEFINITIONS. As used herein, the following
terms shall have the following respective meanings: 
 (a) “Exercise Period” shall mean the period
commencing with the date of this warrant and ending on the Expiration Date, unless terminated earlier in accordance with the terms hereof. 
 (b) “Exercise Price” shall mean one cent ($0.01) per Exercise Share; provided further that the Exercise Price is subject to further adjustment pursuant to Section 5 below.

 (c) “Exercise Shares” shall mean
[                    ] shares of Common Stock of Company, par value $0.001 per share (the “Common Stock”), subject to further adjustment
pursuant to Section 5 below. 
 (d) “Expiration Date” shall mean the seventh anniversary of the date of
issuance hereof. 
 (e) “Investor Rights Agreement” shall mean the Amended and Restated Investor Rights
Agreement dated December 8, 2009, among the Company and the investors named therein, as further amended from time to time. 

2. EXERCISE OF WARRANT. The rights represented by this Warrant may be exercised in
whole or in part at any time during the Exercise Period, by delivery of the following to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder): 

  
 1. 

 (a) An executed Notice of Exercise in the form attached hereto; 

(b) Payment of the Exercise Price either (i) in cash or by check, (ii) by cancellation of indebtedness, or
(iii) through a net exercise pursuant to Section 2.1 below; and 
 (c) This Warrant. 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased,
registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised.
In the event the Warrant is not exercised in full, the Company, at its expense, will forthwith issue and deliver to or upon the order of the Holder a new Warrant or Warrants of like tenor, in the name of the Holder or as the Holder may request,
exercisable for the number of Exercise Shares equal (without giving effect to any adjustment therein) to the total number of such Exercise Shares for which this Warrant is then exercisable minus the number of Exercise Shares (without giving effect
to any adjustment therein) for which this Warrant shall have been exercised. 
 The person or entity in whose name any
certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was
made, irrespective of the date of delivery of such certificate or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the
holder of such shares at the close of business on the next succeeding date on which the stock transfer books are open. 
 2.1
Net Exercise. Notwithstanding any provisions herein to the contrary, if the fair market value of one Exercise Share is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment
of cash, the Holder may elect to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed
Notice of Exercise in which event the Company shall issue to the Holder a number of Exercise Shares computed using the following formula: 
 X = Y (A-B) 

                         
                A 
  

			
	Where X =	  	the number of Exercise Shares to be issued to the Holder
		
	            Y =	  	the number of Exercise Shares purchasable under the Warrant or, if only a portion of the Warrant is being exercised, that portion of the Warrant being canceled (at the date of such
calculation)
		
	            A =	  	the fair market value of one Exercise Share (at the date of such calculation)
		
	            B =	  	Exercise Price (as adjusted to the date of such calculation)

  
 2. 

 For purposes of the above calculation, prior to the Company’s initial public offering
of its Common Stock (“IPO”), the fair market value of one Exercise Share shall be determined by the Company’s Board of Directors in good faith. If this Warrant is exercised pursuant to this Section 2.1 in connection with the
Company’s IPO, the fair market value per share shall be the per share offering price to the public of the Company’s initial public offering. If this Warrant is exercised after the Company’s IPO, the fair market value per share shall
be determined as follows: 
 (i) if traded on a securities exchange, the fair market value shall be the average of the
closing prices over a five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined;  
 (ii) if actively traded over-the-counter, the fair market value shall be the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day
period ending three (3) days before the day the current fair market value of the securities is being determined; or 

(iii) if not listed on any securities exchange or quoted in the NASDAQ System or the over-the-counter market, the fair market value
shall be determined in good faith by the Company’s Board of Directors. 
 2.2 Exercise in Connection with Public
Offering. Notwithstanding anything to the contrary herein, if an exercise of any portion of this Warrant is to be made in connection with a registered public offering or the sale of the Company, the exercise of this Warrant may, at the election
of the Holder, be conditioned upon the consummation of the public offering or sale of the Company, in which case such exercise shall be deemed to not be effective unless and until such transaction is consummated. 

2.3 Automatic Exercise. Notwithstanding anything to the contrary herein, if any portion of this Warrant has not been exercised as
of immediately prior to the expiration of the Exercise Period, any such unexercised portion of this Warrant shall automatically be deemed to be exercised in full pursuant to the provisions of Section 2.1 hereof, without any further action on
behalf of the Holder, immediately prior to the time this Warrant would otherwise expire pursuant to the terms of this Warrant. 
 3. COVENANTS OF THE COMPANY. The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the rights
represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the
Company will at all times reserve and keep available, solely for issuance and delivery on the exercise of this Warrant, and free from pre-emptive rights, a number of Exercise Shares equal to the total number of Exercise Shares from time to time
issuable upon exercise of this Warrant, and, from time to time, will take all steps necessary to amend its Certificate of Incorporation to provide sufficient reserves of Exercise Shares issuable upon exercise of this Warrant. 

  
 3. 

 4. REPRESENTATIONS OF HOLDER.

 4.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that it is acquiring the
Warrant and the Exercise Shares solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof. The Holder also represents that the entire legal and beneficial
interests of the Warrant and Exercise Shares the Holder is acquiring is being acquired for its account only. 
 4.2
Securities Are Not Registered. 
 (a) The Holder understands that the Warrant and the Exercise Shares have not been
registered under the Securities Act of 1933, as amended (the “Act”) on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present
if, notwithstanding its representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or
otherwise distributing the securities. The Holder has no such present intention. 
 (b) The Holder recognizes that the
Warrant and the Exercise Shares must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register the Warrant or
the Exercise Shares of the Company, or to comply with any exemption from such registration. 
 (c) The Holder is aware
that neither the Warrant nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the availability of certain current public information about the Company, the
resale following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations. Holder is aware that the conditions for resale set forth in Rule 144 have not been
satisfied and that the Company presently has no plans to satisfy these conditions in the foreseeable future. 
 4.3
Disposition of Warrant and Exercise Shares. 
 (a) The Company and the Holder agree that the Warrant and the Exercise
Shares will be subject to the restrictions on transfer set forth in Section 2.1 of the Investor Rights Agreement. 

(b) The Holder understands and agrees that all certificates evidencing the shares to be issued to the Holder may bear the following
legend: 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY
NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

  
 4. 

 4.4 Accredited Investor Status. The Holder is an “accredited investor” as
defined in Regulation D promulgated under the Act. 
 5. ADJUSTMENT OF
EXERCISE PRICE. 
 5.1 Changes in Securities. In the event of changes in the outstanding
Common Stock of the Company by reason of stock dividends, splits, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, consolidation, merger, liquidations, or the like, the number and class of
shares available under the Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the
Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment; provided, however, that such adjustment shall not be made with respect to, and
this Warrant shall terminate if not exercised prior to, the events set forth in Section 7 below. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant. 

5.2 Continuation of Terms. Subject to Section 7, upon any reorganization, consolidation or merger (and any liquidation
following any such event) referred to in this Section 5, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the shares of stock and other securities and property receivable on the exercise of this
Warrant after the consummation of such reorganization, consolidation or merger, or the effective date of liquidation following any such event, as the case may be, and shall be binding upon the issuer of any stock or other securities in such event,
whether or not such person shall have expressly assumed the terms of this Warrant. 
 6. FRACTIONAL
SHARES. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated
for purposes of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional
share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction. 

7. EARLY TERMINATION. In the event of an Acquisition or Asset Transfer (as such terms are defined in
the Company’s Certificate of Incorporation, as may be amended from time to time, and each, an “Acquisition Event”), in which the consideration paid to the Company or its stockholders consists of cash and/or publicly traded securities,
then the Company shall provide to the Holder ten (10) days advance notice of such Acquisition Event, and this Warrant shall terminate unless exercised prior to the consummation of the Acquisition Event. 

  
 5. 

 8. MARKET STAND-OFF
AGREEMENT. Holder agrees that the market stand-off agreement in Section 2.11 of the Investor Rights Agreement shall apply to the Warrant and the Exercise Shares. 

9. NO STOCKHOLDER RIGHTS. This Warrant in and of itself shall not entitle the Holder
to any voting rights or other rights as a stockholder of the Company. 
 10. LOST,
STOLEN, MUTILATED OR DESTROYED WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may
reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an
original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 
 11. NOTICES, ETC. All notices and other communications required or permitted hereunder shall be in writing and shall be sent by telex, telegram, express mail or other
form of rapid communications, if possible, and if not then such notice or communication shall be mailed by first-class mail, postage prepaid, addressed in each case to the party entitled thereto at the following addresses: (a) if to the
Company, to Revance Therapeutics, Inc., Attention: Chief Financial Officer, 7555 Gateway Boulevard, Newark, CA 94560 and (b) if to the Holder, to the address stated herein, or at such other address as one party may furnish to the other in
writing. Notice shall be deemed effective on the date dispatched if by personal delivery, telecopy, telex or telegram, two days after mailing if by express mail, or three days after mailing if by first-class mail. In the event of any Acquisition
Event, the Company shall provide to the Holder ten (10) days advance notice of such Acquisition Event. 
 12.
ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. 
 13. AMENDMENT. Any term of this Warrant may be amended or waived with the written consent of the Company and the Requisite Holders (as defined in the Notes) and shall be binding upon
Holder; provided, however, that no amendment or waiver shall adversely affect the rights of the Holder of this Warrant in a different or disproportionate manner relative to the other holders of other Warrants issued pursuant to the Agreement, unless
such amendment or waiver is agreed to by the Holder of this Warrant.  
 14. GOVERNING
LAW. This Warrant and all rights, obligations and liabilities hereunder shall be governed by and construed under the laws of the State of California as applied to agreements among California residents, made and to be performed
entirely within the State of California without giving effect to conflicts of laws principles. 

  
 6. 

 IN WITNESS WHEREOF, the
Company has caused this WARRANT to be executed by its duly authorized officer as of the first date set forth above. 

 

			
	REVANCE THERAPEUTICS, INC.
		
	 By:
	 	  

		 	 L. Daniel Browne,

		 	 President and Chief Executive Officer

 NOTICE OF EXERCISE 
 TO: REVANCE THERAPEUTICS, INC. 

(1)      ̈     The undersigned hereby elects
to purchase                     shares of Common Stock of Revance Therapeutics, Inc. (the “Company”) pursuant
to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full. 

           ̈     The
undersigned hereby elects to purchase             shares of Common Stock of the Company pursuant to the terms of the net exercise provisions set forth in Section 2.1 of the attached
Warrant. 
 (2) Please issue a certificate or certificates representing said shares of stock in the name of the
undersigned or in such other name as is specified below: 
  

					
	  

(Name)
	  		  	  

		  		  	  
 (Address)

 (3) The undersigned represents that (i) the aforesaid shares are being acquired for the
account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is
aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) undersigned is
experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own
interests; (iv) undersigned understands that the shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the
registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they
must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) undersigned is aware that the aforesaid shares may not be sold pursuant to Rule 144 adopted under the
Securities Act unless certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current information to the public
about the Company and the Company has not made such information available and has no present plans to do so; (vi) undersigned agrees not to make any disposition of all or any part of the aforesaid shares unless and until there is then in effect
a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has provided the Company with an opinion of counsel satisfactory to
the Company, stating that such registration is not required; and (vii) undersigned agrees to continue to be bound by the terms of the Warrant, including the market stand-off agreement in Section 8. 

 

							
	Date:
                                        
                        	 		 	By:	 	  

				
		 		 	Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]